May elevated lipoprotein(a) levels in euthyroid autoimmune disease increase the risk of arteriosclerosis?

被引:0
作者
Buchinger, W
Pongratz, R
Binter, G
Eber, O
机构
关键词
lipoprotein(a); euthyroid autoimmune disease; arteriosclerosis; lipid metabolism; hypothyroidism;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Elevated serum levels of lipoprotein(a) [Lp(a)] represent an independent risk factor in the development of arteriosclerosis and coronary heart disease. In overt but also in subclinical hypothyroidism a reversible increase of Lp(a) occurs. We compared Lp(a) serum levels, cholesterol, triglyceride, HDL- and LDL-cholesterol in 19 hypothyroid patients prior to and following the state of euthyroidism (group 1). On the other hand in group 2 we investigated 20 euthyroid patients having elevated thyroid antibodies as against 50 euthyroid normolipemic control subjects without detectable thyroid antibodies. Group 1: The elevated Lp(a) serum levels of the hypothyroid patients decreased significantly in the euthyroid state (37.9 +/- 8.24 vs. 28.1 +/- 6.13 mg/dl, mean +/- SEM). Group 2: The mean Lp(a) serum levels of the patients with increased thyroid antibodies were significantly higher than those of the control group (24.8 +/- 5.78 vs. 9.6 +/- 1.56 mg/dl, mean +/- SEM). In other parameters of lipid metabolism and thyroidal function no significant differences between both groups could be seen. The question arises whether such isolated Lp(a) elevation will lead to an increased arteriosclerotic risk. To minimize this possible risk regular controls of thyroid function should be carried out in euthyroid patients with elevated thyroid antibodies. In this way hypothyroidism may be detected and treated at an early stage.
引用
收藏
页码:78 / 81
页数:4
相关论文
共 50 条
  • [41] Prediction of 10-year cardiovascular disease risk by diabetes status and lipoprotein-a levels; the HellenicSCORE II
    Panagiotakos, Demosthenes
    Chrysohoou, Christina
    Pitsavos, Christos
    Tsioufis, Konstantinos
    HELLENIC JOURNAL OF CARDIOLOGY, 2024, 79 : 3 - 14
  • [42] Elevated Lipoprotein(a) Concentration and Presence of Subfractions of Small Dense Low Density Lipoproteins as Independent Factors of Risk of Ischemic Heart Disease
    Afanasieva, O. I.
    Utkina, E. A.
    Artemieva, N. V.
    Ezhov, M. V.
    Adamova, I. Yu.
    Pokrovsky, S. N.
    KARDIOLOGIYA, 2016, 56 (06) : 5 - 11
  • [43] Elevated Lipoprotein(a) prevalence and association with family history of premature cardiovascular disease in general population with moderate cardiovascular risk and increased LDL cholesterol
    Gulayin, Pablo E.
    Lozada, Alfredo
    Schreier, Laura
    Gutierrez, Laura
    Lopez, Graciela
    Poggio, Rosana
    Mores, Nora
    Ponzo, Jacqueline
    Calandrelli, Matias
    Lanas, Fernando
    Irazola, Vilma
    IJC HEART & VASCULATURE, 2022, 42
  • [44] Elevated lipoprotein(a) and risk of coronary heart disease according to different lipid profiles in the general Chinese community population: the CHCN-BTH study
    Guo, Chunyue
    Cao, Han
    Shan, Guangliang
    Zhao, Wei
    Zhang, Han
    Niu, Kaijun
    Cui, Ze
    Tang, Naijun
    Liu, Kuo
    Pan, Li
    Han, Xiaoyan
    Wang, Zhengfang
    Meng, Ge
    Sun, Jixin
    Shan, Anqi
    Yan, Yuxiang
    He, Huijing
    Xu, Zhiyuan
    Cao, Yajing
    Peng, Wenjuan
    Sun, Yanyan
    Xie, Yunyi
    Liu, Xiaohui
    Li, Bingxiao
    Wen, Fuyuan
    Zhang, Ling
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (01)
  • [45] The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease: Differences between men and women
    Hahmann, HW
    Schatzer-Klotz, D
    Bunte, T
    Becker, D
    Schieffer, HJ
    ATHEROSCLEROSIS, 1999, 144 (01) : 221 - 228
  • [46] Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women
    Shek, Aleksandr B.
    Alieva, Rano B.
    Abdullaev, Alisher A.
    Fozilov, Khurshid G.
    Khoshimov, Shavkat U.
    Abdullaeva, Guzal J.
    Zakirova, Darya V.
    Kurbanova, Rano A.
    Kan, Lilya E.
    Kim, Andrey R.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (08)
  • [47] Lipoprotein (a) levels in those with high molecular weight apo (a) isoforms may remain low in a significant proportion of patients with end-stage renal disease
    Parsons, DS
    Reaveley, DA
    Pavitt, DV
    Misral, M
    Brown, EA
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (09) : 1848 - 1853
  • [48] Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease
    Atiq, Ferdows
    Meijer, Karina
    Eikenboom, Jeroen
    Fijnvandraat, Karin
    Mauser-Bunschoten, Eveline P.
    van Galen, Karin P. M.
    Nijziel, Marten R.
    Ypma, Paula F.
    de Meris, Joke
    Laros-van Gorkom, Britta A. P.
    van der Bom, Johanna G.
    de Maat, Moniek P.
    Cnossen, Marjon H.
    Leebeek, Frank W. G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (01) : 93 - 105
  • [49] Cardiovascular risk assessment and treatment to target low density lipoprotein levels in hospitalized ischemic heart disease patients: Results of the HOLEM study
    Harats, D
    Leibovitz, E
    Maislos, M
    Wolfovitz, E
    Chajek-Shaul, T
    Leitersdorf, E
    Gavish, D
    Gerber, Y
    Goldbourt, U
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2005, 7 (06): : 355 - 359
  • [50] Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study
    Perrot, Nicolas
    Verbeek, Rutger
    Sandhu, Manjinder
    Boekholdt, S. Matthijs
    Hovingh, G. Kees
    Wareham, Nicholas J.
    Khaw, Kay-Tee
    Arsenault, Benoit J.
    ATHEROSCLEROSIS, 2017, 256 : 47 - 52